Habitat and peritumoral CT radiomics accurately predict early treatment response to hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and programmed death−1 inhibitors in unresectable hepatocellular carcinoma

Background The pronounced heterogeneity of hepatocellular carcinoma (HCC) leads to variable responses to hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and PD-1 inhibitors (HTP therapy). This study aimed to develop and validate a combined model integrating habitat radiomics, peritumoral radiomics, and clinical factors to predict early treatment response in patients with unresectable HCC receiving HTP therapy. Methods This retrospective two-center study enrolled 2